Advertisement
U.S. markets close in 2 hours 31 minutes

Cell MedX Corp. (CMXC)

Other OTC - Other OTC Delayed Price. Currency in USD
0.02400.0000 (0.00%)
As of 12:50PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0240
Open0.0298
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0240 - 0.0298
52 Week Range0.0002 - 0.9312
Volume14,537
Avg. Volume16,749
Market Cap7.074M
Beta (5Y Monthly)32.44
PE Ratio (TTM)N/A
EPS (TTM)-0.0100
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for CMXC

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • CELL MEDX CORP
    Weekly Stock ListWe see what we believe are some great opportunities right now in Healthcare -- and we like the sector overall. Argus Director of Research Jim Kelleher, CFA, recently completed his quarterly sector review and raised Healthcare sector to Over-Weight from Market-Weight. The healthcare environment is undergoing rapid transitions, and we now see an unfolding period of significant promise and opportunity. Our newly-favored stance is based on resumption of deferred medical procedures and significant new quality-of-life drugs and treatments. The category is broad and has underperformed the S&P 500 over the past year. The Healthcare sector ETF (XLV) is up 15% over the past year compared to a gain of 31% for the S&P 500. We see opportunity here to pick up some steady companies, with big brands and solid financials. These companies are science-focused and enhance lives. They are innovators. In our list this week, we look across several subsectors within the Healthcare sector and pull out some leaders we like. These stocks also are included in our Focus List and Model Portfolios, as noted below.
    Rating
    Fair Value
    Economic Moat
    10 days agoArgus Research
View more
  • Newsfile

    Cell MedX Corp. Closes Private Placement Financing

    Vancouver, British Columbia--(Newsfile Corp. - March 19, 2024) - Cell MedX Corp. (OTC Pink: CMXC) ("Cell MedX", or the "Company") a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote anti-aging and general wellness, announces that it has closed a non-brokered private placement offering (the "Offering") by issuing 2,500,000 units (each a "Unit") at US$0.03 per Unit for total gross proceeds of US$75,000. Each Unit s

  • Newsfile

    Cell MedX Corp. Announces Resignation of Director

    Vancouver, British Columbia--(Newsfile Corp. - February 28, 2024) - Cell MedX Corp. (OTC Pink: CMXC) ("Cell MedX", or the "Company") a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote anti-aging and general wellness, announces the resignation of Brad Hargreaves from the Board of Directors of the Company. The resignation of Mr. Hargreaves was not due to any disagreement with the Company on any matter relating to

  • Newsfile

    Cell MedX Corp. Appoints Dr. George Adams as Chairman of the Board

    Vancouver, British Columbia--(Newsfile Corp. - February 26, 2024) - Cell MedX Corp. (OTC Pink: CMXC) ("Cell MedX", or the "Company") a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote anti-aging and general wellness, is pleased to announce the appointment by the board of directors of Dr. George Adams as Chairman of the Board.Dr. Adams has served on the board of directors of the Company since March ...